ABBV AbbVie Inc

Price (delayed)

$141.99

Market cap

$251.05B

P/E Ratio

20.03

Dividend/share

$5.53

EPS

$7.09

Enterprise value

$315.46B

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories. On October 19, 2011, Abbott Laboratories announced its plan to separate ...

Highlights
The EPS has soared by 93% YoY
The company's net income has surged by 90% YoY
AbbVie's equity has increased by 17% YoY but it has decreased by 10% from the previous quarter
The quick ratio has grown by 9% from the previous quarter but it has contracted by 6% YoY

Key stats

What are the main financial stats of ABBV
Market
Shares outstanding
1.77B
Market cap
$251.05B
Enterprise value
$315.46B
Valuations
Price to earnings (P/E)
20.03
Price to book (P/B)
17.12
Price to sales (P/S)
4.38
EV/EBIT
19.37
EV/EBITDA
12.88
EV/Sales
5.5
Earnings
Revenue
$57.35B
EBIT
$16.29B
EBITDA
$24.5B
Free cash flow
$22.21B
Per share
EPS
$7.09
Free cash flow per share
$12.55
Book value per share
$8.29
Revenue per share
$32.4
TBVPS
$22.22
Balance sheet
Total assets
$143.19B
Total liabilities
$128.5B
Debt
$72.93B
Equity
$14.65B
Working capital
-$5.37B
Liquidity
Debt to equity
4.98
Current ratio
0.84
Quick ratio
0.61
Net debt/EBITDA
2.63
Margins
EBITDA margin
42.7%
Gross margin
70.5%
Net margin
22%
Operating margin
30.3%
Efficiency
Return on assets
8.7%
Return on equity
84.4%
Return on invested capital
22.5%
Return on capital employed
15%
Return on sales
28.4%
Dividend
Dividend yield
3.89%
DPS
$5.53
Payout ratio
78%

ABBV stock price

How has the AbbVie stock price performed over time
Intraday
2.65%
1 week
0.19%
1 month
4.19%
1 year
30.59%
YTD
4.87%
QTD
5.8%

Financial performance

How have AbbVie's revenue and profit performed over time
Revenue
$57.35B
Gross profit
$40.42B
Operating income
$17.39B
Net income
$12.64B
Gross margin
70.5%
Net margin
22%
The company's net income has surged by 90% YoY
The net margin has surged by 77% year-on-year
ABBV's gross profit is up by 15% year-on-year and by 2.5% since the previous quarter
The operating income has grown by 12% YoY but it has contracted by 6% from the previous quarter

Growth

What is AbbVie's growth rate over time

Valuation

What is AbbVie stock price valuation
P/E
20.03
P/B
17.12
P/S
4.38
EV/EBIT
19.37
EV/EBITDA
12.88
EV/Sales
5.5
The EPS has soared by 93% YoY
ABBV's P/E is 19% below its 5-year quarterly average of 24.8 and 13% below its last 4 quarters average of 22.9
AbbVie's equity has increased by 17% YoY but it has decreased by 10% from the previous quarter
ABBV's price to book (P/B) is 4.4% higher than its last 4 quarters average of 16.4
ABBV's revenue is up by 7% year-on-year
ABBV's P/S is 7% above its 5-year quarterly average of 4.1

Efficiency

How efficient is AbbVie business performance
AbbVie's ROIC has soared by 121% YoY and by 4.2% from the previous quarter
AbbVie's return on assets has surged by 93% YoY and by 2.4% QoQ
The ROS has soared by 80% YoY
The ROE has soared by 73% YoY but it has contracted by 2.2% from the previous quarter

Dividends

What is ABBV's dividend history
DPS
$5.53
Dividend yield
3.89%
Payout ratio
78%
Recent dividends

Financial health

How did AbbVie financials performed over time
AbbVie's total assets is 11% higher than its total liabilities
The quick ratio has grown by 9% from the previous quarter but it has contracted by 6% YoY
ABBV's current ratio is down by 8% year-on-year but it is up by 2.4% since the previous quarter
The company's debt to equity fell by 24% YoY but it rose by 10% QoQ
AbbVie's equity has increased by 17% YoY but it has decreased by 10% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.